AnaptysBio, Inc. (ANAB) |
| 48.125 -0.905 (-1.85%) 01-13 16:00 |
| Open: | 48.64 |
| High: | 49.43 |
| Low: | 46.52 |
| Volume: | 321,055 |
| Market Cap: | 1,333(M) |
| PE Ratio: | -17.07 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 61.28 |
| Resistance 1: | 52.47 |
| Pivot price: | 47.40 |
| Support 1: | 46.07 |
| Support 2: | 42.12 |
| 52w High: | 52.47 |
| 52w Low: | 12.21 |
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| EPS | -2.820 |
| Book Value | -1.070 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.595 |
| Profit Margin (%) | -49.94 |
| Operating Margin (%) | 45.47 |
| Return on Assets (ttm) | -4.2 |
| Return on Equity (ttm) | -308.0 |
Mon, 12 Jan 2026
AnaptysBio (NASDAQ:ANAB) Stock Price Up 7.2% - Time to Buy? - MarketBeat
Fri, 09 Jan 2026
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock By Investing.com - Investing.com South Africa
Fri, 09 Jan 2026
Anaptysbio (ANAB) chief medical officer sells $163,191 in stock - Investing.com
Thu, 08 Jan 2026
AnaptysBio, Inc. Files Motion to Dismiss Breach of Contract Claim Amid Ongoing Dispute with Tesaro and GSK, Trial Set for July 2026 - Quiver Quantitative
Thu, 08 Jan 2026
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 9,639 Shares - MarketBeat
Thu, 08 Jan 2026
Insider Selling: AnaptysBio (NASDAQ:ANAB) CEO Sells $415,102.22 in Stock - MarketBeat
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |